Ferring Pharmaceuticals 보도자료

2019년 11월 26일 09:11

Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients

Ferring Pharmaceuticals and Blackstone Life Sciences today announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in late stage development for patients with high-g...

2019년 7월 10일 10:35

Heat-stable carbetocin has been added to the WHO Essential Medicines List for the prevention of excessive bleeding after childbirth

Ferring Pharmaceuticals today welcomes the World Health Organization’s (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML) of uterotonics for the prevention of excessive bleeding after birth.[1] The EML iden...

2019년 6월 19일 16:12

Ferring Collaboration with Digital Health Innovators WOOM Aims to Help More People Build Families Faster

Ferring Pharmaceuticals and WOOM today announced a collaboration, which aims to improve and shorten the fertility journeys of the one in six couples who have difficulty conceiving.[1] The WOOM ovulation and fertility app, currently available in Sp...

2019년 1월 22일 16:15

Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments

Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology. The collaboration bri...

2018년 10월 31일 18:35

Ferring Announces Retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer

Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities effective December 31, 2018. Per Falk, Chief Science Officer, will assume addi...

2018년 10월 17일 17:40

Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health

Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and g...

2018년 8월 31일 10:50

Ferring and Celmatix Launch Ambitious Genomics Collaboration to Advance Care in Reproductive Medicine and Women’s Health

Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian biology and accelerating the development of personalized interventions in reproductive medicine and women’s heal...

2018년 7월 24일 09:05

Ferring’s Heat-Stable Carbetocin Could Save Thousands of Women’s Lives by Preventing Excessive Bleeding after Childbirth

Ferring Pharmaceuticals today announced new data demonstrating that its heat-stable formulation of carbetocin is as effective as the current standard of care, oxytocin, for the prevention of excessive bleeding, also known as postpartum haemorrhage...

2018년 7월 3일 18:50

New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment

Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial[1] showing that natural variations in anti-Müllerian hormone (AMH) levels during and between a woman’s menstrual cycle have no clinically relevant impa...

2018년 5월 30일 09:50

Large-Scale Study Provides First-Ever Insights into the Genetic Causes of Bedwetting

New evidence from the world’s first genome-wide association study (GWAS) identifies genes and genetic variants associated with bedwetting and may lead to earlier identification of children predisposed to bedwetting and improved earlier treatment o...

2018년 5월 30일 09:50

대규모 연구를 통해 야뇨증의 유전학적 원인 세계 최초로 밝혀내

2018년 5월 4일 10:15

Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients

Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy being developed by FKD Therapies Oy (...

2018년 4월 6일 09:40

Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and underst...

2018년 3월 15일 17:10

Ferring Announces Positive Outcome of European Decentralised Procedure (DCP) for Testavan®, a Treatment for Men with Hypogonadism

Ferring Pharmaceuticals today announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan® (transdermal testosterone gel 2%), a testosterone replacement therapy for adult male hypogonadism, when testosterone deficienc...

2018년 3월 7일 15:15

March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London

March of Dimes and Ferring Pharmaceuticals today announced that March of Dimes has selected Imperial College London as the first European partner to join its network of Prematurity Research Centers working to find the unknown causes of preterm bir...

2018년 2월 22일 16:25

Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage

Ferring Pharmaceuticals and MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the...

2018년 2월 15일 11:00

Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland

Ferring Pharmaceuticals announced today that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland. Over the next...

2018년 1월 26일 16:00

Ferring Announces Recipients of Innovation Grants Program 2017-2018

Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego. This global program supports research in the fields of reproductive...

2018년 1월 23일 09:25

Ferring enters into worldwide OmniAb® platform license agreement with Ligand

Ferring Pharmaceuticals announced today that it has entered into a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies for a range of indications. Under the agreement...

2018년 1월 11일 19:25

Ferring and the Chinese Academy of Sciences Collaborate to Advance Research in Reproductive Medicine

Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) today announced a long-term collaboration to advance basic and translational research in reproductive medicine through the development of novel product candidates and therapeutic st...

2017년 11월 27일 15:35

Ferring Receives Swiss Approval For Rekovelle®, The First Personalised Fertility Treatment Using an Approved Dosing Algorithm

Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (AR...

2017년 10월 12일 11:50

Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector Device

Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc. to acquire the worldwide rights for the ZomaJet™ needle-free auto injector device. This transaction is subject to customary closing c...

2017년 10월 2일 14:56

Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer

Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately. He will be responsible for Global Medical Affairs, Quality Assurance and Pharmacovigila...

2017년 7월 3일 16:40

Ferring Appoints Lars Peter Brunse to Executive Board

Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective immediately. Lars Peter Brunse joined Ferring as A...

2017년 6월 2일 11:45

Ferring Appoints Aaron Graff to Executive Board

Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective immediately. Aaron Graff joined Ferring in 2002 as ...

Ferring Pharmaceuticals